Skip to content Skip to footer
Join our LinkedIn Group and be part of the conversation on AI in life sciences
Login
Close

Meghan Oates-Zalesky 

Meghan Oates‑Zalesky is Chief Marketing Officer at CapeStart and MadeAi, with over 20 years of experience in healthcare technology and life sciences. Previously CMO at Apollo Intelligence, she helped grow the company from a small startup into a global enterprise. A PharmaVOICE Woman of Influence (2021), Meg’s thought leadership has appeared in leading industry publications. She holds degrees from Harvard and the London School of Economics and is a published novelist and avid equestrian.

67 articles published Follow:
i4

MadeAi™ Honored as a Winner in the 2026 Artificial Intelligence Excellence Awards

MadeAi Press Release1 day ago13Views0Likes0Comments
Achievement recognizes organizations, products, teams, and individuals delivering measurable results through artificial intelligence CAMBRIDGE, April 9, 2026—MadeAi, Inc. (MadeAi) today announced it has been named a winner in the 2026 Artificial Intelligence Excellence Awards, in the Generative AI category supporting life sciences. Presented by the Business Intelligence Group, the award recognizes organizations, products, teams, and…

Read More

roche

From Explainable AI Screening to Publication-Grade Evidence for Roche HEOR Team

Case StudyApril 7, 202652Views0Likes0Comments
How do you screen thousands of abstracts with transparency and reproducibility using minimal training data? In this case study, MadeAi partnered with the Roche HEOR team to design and validate an explainable AI pipeline for title and abstract screening in a systematic literature review. Using a structured PICO-based framework, the team screened over 3,300 abstracts…

Read More

front view young handsome man striped shirt working inside conference hall using his silver laptop daytime work activity building scaled 1

2026 Prediction #4: Agentic AI is Revolutionizing the Next Phase of Continuous Evidence Generation in Pharma

BlogMarch 31, 202659Views0Likes0Comments
For years, the pharmaceutical industry has followed a familiar cycle: design a clinical trial, execute it, lock the database, analyze the results, and then wait for the next study to answer remaining questions. Wait for post-market surveillance to show real-world outcomes. Wait for regulators or payers to request more data before approving reimbursement. However, this…

Read More

csl-casestudy

From Social Media Conversations to Publication-Ready Evidence for CSL HEOR Team

Case StudyMarch 27, 202637Views0Likes0Comments
How do you turn unstructured social media conversations into publication-ready evidence in just 4 weeks? In this case study, MadeAi partnered with the CSL HEOR team to identify and curate hereditary angioedema-related conversations from public online sources, with insights supporting a Value in Health Journal article. Using a structured social media listening approach, the team analyzed 3,069 records to…

Read More

Role Based Tool Isolation scaled 1

2026 Prediction #3: Role-Based Tool Isolation: The Gold Standard for Secure Pharma AI

BlogMarch 25, 202643Views0Likes0Comments
The pharmaceutical industry is currently at a pivotal moment in the AI landscape. After years of cautious AI experimentation limited to isolated labs and pilot programs, something fundamentally different is unfolding in 2026. The central question has shifted from “Does AI work?” to “How do we deploy it safely and at scale?” especially in organizations…

Read More